Josh Waldman

in the past, have you seen higher M&A activity drive improved access to biotech wallet share

I wondered if you could comment more on what you're seeing from global pharma accounts here to start the year

Does it seem like visibility on bookings and cancellations is improving at all? Or is it still challenging versus what you were accustomed to historically?

I wondered if you could comment on how durable you expect recent higher growth in PI could be.

any pockets of recent acceleration or decel? Any more color on where the delays hit?

are you factoring in a larger than normal ramp off of the Q1 to get to the full year

Can you remind us how that's dispersed across the Lab and Industrial segments

I'm curious where all you're seeing the impact of stronger demand across the portfolio

I was curious if you could talk through what you're seeing on the service side

does it seem like visibility going into the second half is any better or worse than the visibility you felt you had either coming into the year or into the second quarter

What were the variables that drove the gross impact stepping down to the $60 million or the, I guess, $95 million with the Switzerland change last night

can you remind us what portion of the business is sales to bioproduction OEMs

I think you mentioned softness in The U.S. in the prepared remarks. Is this primarily where you're lowering your outlook in core

Any way to frame up how you're thinking about offsetting the cost impact? I mean do you think more of the offset will come from price

it sounds like the strength in Europe, maybe even the US, was focused within biopharma. I guess, is that right? And I mean, do you -- or did you see an uptick in other markets

can you run through the areas that came in better than expected, either, you know, from a product angle within the subsegments or geographic?

Was the improvement in the quarter, you know, fairly evenly dispersed over the three months?